Ra Capital Management, L.P. Sells 171,963 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 171,963 shares of the stock in a transaction on Monday, April 20th. The shares were sold at an average price of $15.77, for a total transaction of $2,711,856.51. Following the transaction, the director directly owned 2,567,245 shares in the company, valued at approximately $40,485,453.65. This represents a 6.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, April 17th, Ra Capital Management, L.P. sold 458,411 shares of Vor Biopharma stock. The shares were sold at an average price of $16.28, for a total transaction of $7,462,931.08.
• On Monday, April 13th, Ra Capital Management, L.P. sold 530,610 shares of Vor Biopharma stock. The shares were sold at an average price of $16.15, for a total transaction of $8,569,351.50.
• On Wednesday, April 15th, Ra Capital Management, L.P. sold 53,644 shares of Vor Biopharma stock. The shares were sold at an average price of $16.01, for a total transaction of $858,840.44.
• On Tuesday, April 14th, Ra Capital Management, L.P. sold 153,735 shares of Vor Biopharma stock. The shares were sold at an average price of $15.97, for a total transaction of $2,455,147.95.
• On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The shares were sold at an average price of $15.75, for a total transaction of $13,041.00.
• On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total transaction of $2,242,984.59.
• On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The shares were sold at an average price of $16.48, for a total transaction of $7,978,033.92.
• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total transaction of $9,775,773.63.
• On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The shares were sold at an average price of $18.23, for a total transaction of $4,739,800.00.

Vor Biopharma Stock Performance

VOR stock opened at $15.32 on Thursday. Vor Biopharma Inc. has a 52 week low of $2.62 and a 52 week high of $65.80. The firm’s fifty day moving average is $14.84 and its 200 day moving average is $15.81. The firm has a market cap of $748.35 million, a P/E ratio of -0.04 and a beta of 1.92.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Ariose Capital Management Ltd purchased a new stake in shares of Vor Biopharma in the 3rd quarter worth about $5,368,000. Fcpm Iii Services B.V. purchased a new stake in shares of Vor Biopharma in the 3rd quarter worth about $18,496,000. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma in the 2nd quarter worth about $66,000. Goldman Sachs Group Inc. lifted its position in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the period. Finally, Cannon Global Investment Management LLC purchased a new stake in shares of Vor Biopharma in the 1st quarter worth about $209,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on VOR shares. Jefferies Financial Group started coverage on shares of Vor Biopharma in a report on Monday, March 30th. They issued a “buy” rating and a $50.00 price target on the stock. Wall Street Zen raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Saturday, April 4th. Citigroup started coverage on shares of Vor Biopharma in a report on Friday, January 9th. They issued a “buy” rating and a $50.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Finally, Wells Fargo & Company started coverage on shares of Vor Biopharma in a report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Vor Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $50.56.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).